Showing results (1861-1870 of 2,739) with videos related to

Sort By:
Pageof 274
Pharmacogenomics|December 21, 2016
Correlations between the enantio- and regio-selective metabolisms of warfarinHarumi Takahashi, Minami Ohara, Soichi Shibata, et al.
Pharmacogenomics|December 20, 2016
Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysisZhi-Ping Jiang, Xie-Lan Zhao, Naoto Takahashi, et al.
Pharmacogenomics|March 15, 2014
ABCC2 rs2273697 and rs3740066 polymorphisms and resistance to antiepileptic drugs in Asia Pacific epilepsy cohortsHidayati Mohd Sha'ari, Batoul Sadat Haerian, Larry Baum, et al.
Pharmacogenomics|March 15, 2014
MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysisMichael D Morgan, Nashwa Al-Shaarawy, Steve Martin, et al.
Pharmacogenomics|March 15, 2014
Single nucleotide polymorphic macrophage cytokine regulation by Mycobacterium tuberculosis and drug treatmentAmit K Singh, Awadh Bihari Yadav, Rajiv Garg, et al.
Pharmacogenomics|May 7, 2014
Towards a personalized treatment in depression: endocannabinoids, inflammation and stress responseZuzanna E Zajkowska, Amir Englund, Patricia A Zunszain
Pharmacogenomics|May 7, 2014
Epigenetic perspectives on cancer chemotherapy responseMou-Ze Liu, Howard L McLeod, Fa-Zhong He, et al.
Pharmacogenomics|November 23, 2012
Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patientsOlga G Kulakova, Ekaterina Yu Tsareva, Alexey N Boyko, et al.
Pharmacogenomics|November 23, 2012
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patientsMariana Rieck, Artur F Schumacher-Schuh, Vivian Altmann, et al.
Pharmacogenomics|October 11, 2014
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposureJackson K Mukonzo, Sarah Nanzigu, Paul Waako, et al.
Pageof 274